Press release

Zur Rose Group AG publishes invitation to the Annual General Meeting on 23 April 2020

Zur Rose Group AG today has published the invitation to the Annual General Meeting on 23 April 2020. As a result of the extraordinary situation related to the COVID-19 pandemic, this year's Annual General Meeting will be held in accordance with the Ordinance of the Federal Council on Measures to Combat the Coronavirus. Given the measures currently in force, the personal attendance of shareholders at the Annual General Meeting on site will not be possible. Shareholders may only be represented by the independent voting rights representative. The Board of Directors regrets not being able to welcome the shareholders to the Annual General Meeting this year and requests the shareholders to make use of the option to be represented by the independent voting rights representative.

In addition to the standard agenda items of the Annual General Meeting, a proposal for creation of authorized share capital with a nominal value of CHF 39,329,880 as well as a proposal for the creation of additional conditional share capital for financing, acquisitions and other purposes pursuant to which 1,310,996 fully paid up registered shares can be issued are on the agenda of this year's Annual General Meeting. The existing authorized capital in the Articles of Association expired on 19 June 2019. The Board of Directors is proposing to create again authorized capital in order to maintain the financial flexibility of Zur Rose Group AG. The authorized capital proposed is equivalent to 15 percent of the registered share capital of the company, which is in line with comparable companies.

In connection with the placement on March 26, 2020 of CHF 175 million convertible bonds due 2025, the available existing conditional capital of the company will be largely used up. To maintain the financial flexibility of the Company the Board of Directors proposes creating additional conditional capital for financing, acquisitions and other purposes pursuant to which 1,310,996 registered shares can be issued. The proposed conditional capital corresponds to 15 percent of the registered share capital of the company, which is in line with comparable companies.

By proposing the simultaneous creation of authorized capital and conditional capital, the Board of Directors wishes to ensure that it has the flexibility to use the appropriate financing instrument in each case. At the same time, the total number of shares that can be issued from authorized and conditional share capital shall be limited to 15 percent of the currently registered share capital (corresponding to 1,310,996 registered shares). Consequently, the Board of Directors proposes the creation of a new provision in the Articles of Association pursuant to which the total number of shares which may be issued from (i) authorized share capital where the preemptive rights were restricted or excluded and from (ii) the new conditional capital for financing, acquisitions and other purposes where the advance subscription rights were restricted or excluded will be limited to 1,310,996 registered shares.

The invitation to the Annual General Meeting of Zur Rose Group AG with the full agenda, proposals and explanations of the Board of Directors plus further information is available at | Investors & Media | General Meeting or at the following link

The voting results will be published by press release and at , "Investors & Media", "Press Releases" shortly after the Annual General Meeting.

Investors and analyst contact
Marcel Ziwica, Chief Financial Officer
Email: , phone: 9

Media contact
Lisa Lüthi, Head of Group Communications
Email: , phone: 4

Agenda
16 April 2020 First Quarter Trading Update
23 April 2020 Annual General Meeting
19 August 2020 Half-Year Results
21 October 2020 Q3 Trading Update

Zur Rose Group

The Swiss Zur Rose Group is Europe's largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany's best-known pharmacy brand DocMorris. Zur Rose employs more than 1,800 people at sites in Switzerland, Germany, the Netherlands, Spain and France. In 2019 it generated revenue of CHF 1,569 million (including medpex) and has around seven million active customers in core European markets.

With its business model, the Zur Rose Group offers high-quality, safe and cost-effective pharmaceutical care. It is also characterized by the continuous further development of digital services in the field of drug management using AI-supported applications and new technology. Zur Rose is furthermore actively driving ahead its positioning as a comprehensive provider of healthcare services. By creating a digital healthcare platform - the Zur Rose ecosystem - it networks products and digital services from qualified providers. The contribution made by Zur Rose will be to take these offerings to customers and patients and to make a relevant selection. The aim is to provide people with a seamless accompaniment and empower them to manage their own health optimally using products and digital solutions.

The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information please see zurrosegroup.com.